Minsa announces that the use of medical and therapeutic cannabis is already regulated

The executive released the regulation that regulates the medical and therapeutic use of cannabis and its derivatives. The document consists of 14 chapters, 50 articles and 14 complementary provisions in order to benefit thousands of patients who need this contribution for their medical treatments.

He Ministry of Health (Minsa), by Directorate General for Medicines, Supplies and Medicines (Digemid), the Directorates of Integrated Health Networks or those who act in their place, as competent authorities, will be responsible for issuing licenses for the production, import, marketing and licenses for the artisanal production of cannabis derivatives with associative cultivation of the plant of the genus cannabis.

There Mediator He highlighted the approval and publication of the settlement and recalled that the settlement had been pending for over a year.

GlobeLiveMedia

The entity in charge of National Registry of Patients Using Cannabis and its Derivatives for Medical and Therapeutic Use (RENPUC) is the Digemid. In order for a patient to be registered in the registry, he must submit a virtual affidavit on the Digemid web portal with information about the disease, the attending physician, the dose and the frequency of treatment.

The regulations state that only surgeons are authorized to prescribe cannabis derivatives for medicinal and therapeutic purposes by a medical prescription which must contain the following information:

– Surnames and first names of the surgeon, school number, telephone number and address.

– Surnames and first names, address, telephone number and patient identifier.

– Medical diagnosis.

– Name of the cannabis derivative and its international nonproprietary name, if applicable.

– Details of the active ingredient, duration of treatment and number of units per injection per day.

Additionally, it is required that The validity of the prescription will be 30 days.from its issue and once the product has been issued, the prescription will be kept by the apothecary or pharmacy, depositing the document for two years.

Only surgeons are authorized to prescribe cannabis derivatives for medicinal and therapeutic purposes.
Only surgeons are authorized to prescribe cannabis derivatives for medicinal and therapeutic purposes.

The regulations indicate the types of licenses that can be issued for the medical and therapeutic use of cannabis and its derivatives. The validity period of the licenses granted is indefinite and must be granted within a period not exceeding 30 days.

License for scientific research: It is exclusive to universities and institutions that conduct agricultural and health research and health science research for medicinal purposes.

Import and marketing license: It is granted to pharmaceutical laboratories, drugstores, pharmacies, apothecaries and pharmacies in health establishments.

Manufacturing license: It is granted only to public entities or pharmaceutical laboratories.

Craft production license: it is granted to duly accredited and certified patient associations.

The regulations specify that the Cannabis Patient Associations They may be composed of two or more patients or legal representatives, previously registered with RENPUC. In addition, they must be accredited and certified.

In interview with RPP News, Digemid specialist in controlled product issues, Judith Castaneda explained that the regulation gives duly accredited patient associations the possibility of developing their own cannabis derivatives for medical and therapeutic use.

Artisanal production is allowed.
Artisanal production is allowed.

Categorized in: